PMID- 21287665
OWN - NLM
STAT- MEDLINE
DCOM- 20120117
LR  - 20220330
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Linking)
VI  - 17
IP  - 10
DP  - 2011 Oct
TI  - Long-term outcome of treatment with infliximab in pediatric-onset Crohn's 
      disease: a population-based study.
PG  - 2144-52
LID - 10.1002/ibd.21615 [doi]
AB  - BACKGROUND: We examined short- and long-term benefits and safety of infliximab 
      (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old 
      at diagnosis. METHODS: The following parameters were assessed: short- and 
      long-term efficacy of IFX, impact of drug efficacy, and mode of administration on 
      rate of resection surgery, growth and nutritional catch-up, and adverse events 
      (AEs). RESULTS: In all, 120 patients (69 female) required IFX with a median 
      duration of 32 months (Q1 = 8-Q3 = 60). Median age at diagnosis was 14.5 years 
      (12-16) and median interval between diagnosis and IFX initiation was 41 months 
      (22-78). Median follow-up since CD diagnosis was 111 months (75-161). Fifty 
      patients (42%) received episodic and 70 (58%) maintenance therapy. Sixty-five 
      (54%) patients were in the "IFX efficacy" group: 38 (32%) still receiving IFX at 
      the last visit and 27 (22%) stopping IFX while in remission. The "IFX failure" 
      group included 55 (46%) patients: 17 (14%) who stopped IFX due to AEs and 38 
      (32%) nonresponders. The risk of surgery was reduced (P = 0.009) in the "IFX 
      efficacy" group and lower (P = 0.03) in patients with scheduled versus episodic 
      therapy. Patients in the "IFX efficacy" group had significant catch-up growth (P 
      = 0.04), while those in the "IFX failure" group did not. Twenty-four patients 
      presented AEs leading to cessation of IFX in 17 of them. CONCLUSIONS: In this 
      population-based cohort of pediatric-onset CD, IFX treatment was effective in 
      more than half of patients during a median follow-up of 32 months. Long-term IFX 
      responders had a lower rate of surgery and improved catch-up in growth, 
      especially when receiving scheduled IFX therapy.
CI  - Copyright (c) 2011 Crohn's & Colitis Foundation of America, Inc.
FAU - Crombe, Valerie
AU  - Crombe V
AD  - Gastroenterology Unit, EPIMAD Registry, Lille University Hospital, Lille, France.
FAU - Salleron, Julia
AU  - Salleron J
FAU - Savoye, Guillaume
AU  - Savoye G
FAU - Dupas, Jean-Louis
AU  - Dupas JL
FAU - Vernier-Massouille, Gwenola
AU  - Vernier-Massouille G
FAU - Lerebours, Eric
AU  - Lerebours E
FAU - Cortot, Antoine
AU  - Cortot A
FAU - Merle, Veronique
AU  - Merle V
FAU - Vasseur, Francis
AU  - Vasseur F
FAU - Turck, Dominique
AU  - Turck D
FAU - Gower-Rousseau, Corinne
AU  - Gower-Rousseau C
FAU - Lemann, Marc
AU  - Lemann M
FAU - Colombel, Jean-Frederic
AU  - Colombel JF
FAU - Duhamel, Alain
AU  - Duhamel A
LA  - eng
PT  - Journal Article
DEP - 20110201
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Gastrointestinal Agents)
RN  - B72HH48FLU (Infliximab)
RN  - Pediatric Crohn's disease
SB  - IM
MH  - Adolescent
MH  - Age of Onset
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Child
MH  - Crohn Disease/*drug therapy/*epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Infliximab
MH  - Male
MH  - Remission Induction
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2011/02/03 06:00
MHDA- 2012/01/18 06:00
CRDT- 2011/02/03 06:00
PHST- 2010/11/18 00:00 [received]
PHST- 2010/11/28 00:00 [accepted]
PHST- 2011/02/03 06:00 [entrez]
PHST- 2011/02/03 06:00 [pubmed]
PHST- 2012/01/18 06:00 [medline]
AID - 10.1002/ibd.21615 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2011 Oct;17(10):2144-52. doi: 10.1002/ibd.21615. Epub 2011 Feb 
      1.